Sfoglia per Rivista CANCER TREATMENT REVIEWS
35 DNA DOUBLE STRANDS BREAK REPAIR GENES EXPRESSION ANALYSIS REVEAL RAD51 AS A NEW POTENTIAL BIOMARKER IN BREAST CANCER.
2010-01-01 Barbano, R; Copetti, M; Perrone, G; Muscarella, La; Balsamo, T; Poeta, Ml; Valori, Vm; Latiano, T; Maiello, E; Carella, M; Pellegrini, F; Murgo, R; A Onetti Muda, ; Fazio, V. M.; Parrella, P
45 GENE EXPRESSION OF SOMATOSTATIN RECEPTOR SUBTYPES SSTR2a, SSTR3 AND SSTR5 IN PERIPHERAL BLOOD OF NEUROENDOCRINE LUNG CANCER AFFECTED PATIENTS
2010-01-01 La, Muscarella; V, D'Alessandro; A La, Torre; M, Freda; M, Copetti; P, Parrella; R, Boragine; F, Pellegrini; E, Maiello; V, Frusciante; Fazio, V. M.; G, Vendemmiale
66 ABERRANT GENES PROMOTER METHYLATION IN NEURAL-CREST DERIVED TUMOURS
2010-01-01 La, Muscarella; A La, Torre; P, Parrella; T, Balsamo; M, Bisceglia; R, Barbano; E, Perrella; Ml, Poeta; G, Melchionda; G, Merla; R, Pellicano; Fazio, V. M.
Adjuvant colon cancer chemotherapy: where we are and where we'll go
2010-01-01 Lombardi, L; Morelli, F; Cinieri, S; Santini, D; Silvestris, N; Fazio, N; Orlando, L; Tonini, G; Colucci, G; Maiello, E
Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME).
2018-01-01 Imbimbo, M1; Ottaviano, M2; Vitali, M3; Fabbri, A4; Leuzzi, G5; Fiore, M6; Franceschini, D7; Pasello, G8; Perrino, M9; Schiavon, M10; Pruneri, G4; Dei Tos, Ap11; Sangalli, C12; Garassino, Mc3; Berardi, R13; Alessi, A14; Calareso, G15; Petrini, I16; Scorsetti, M17; Scotti, V18; Rosso, L19; Rea, F10; Pastorino, U5; Casali, Pg20; Ramella, S; Ricardi, U21; Abate-Daga, L22; Torri, V23; Trama, A24; Palmieri, G2; Marino, M25; Zucali, Pa9; TYME network, Collaborators.
Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: An individual patient data-based pooled analysis of two randomized studies and a systematic review of the literature
2022-01-01 Lombardi, P.; Rossini, D.; Crespi, V.; Germani, M. M.; Bergamo, F.; Pietrantonio, F.; Santini, D.; Allegrini, G.; Daniel, F.; Pagani, F.; Antoniotti, C.; Zaniboni, A.; Conca, V.; Latiano, T. P.; Boccaccino, A.; Passardi, A.; Tamburini, E.; Masi, G.; Di Maio, M.; Cremolini, C.
Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma
2010-01-01 Bronte, G; Rizzo, S; La Paglia, L; Adamo, V; Siragusa, S; Ficorella, C; Santini, D; Bazan, V; Colucci, G; Gebbia, N; Russo, A
New molecular targets in bone metastases
2010-01-01 Santini, D; Galluzzo, S; Zoccoli, A; Pantano, F; Fratto, Me; Vincenzi, B; Lombardi, L; Gucciardino, C; Silvestris, N; Riva, E; Rizzo, S; Russo, A; Maiello, E; Colucci, G; Tonini, G
Overcoming dynamic molecular heterogeneity in metastatic colorectal cancer: Multikinase inhibition with regorafenib and the case of rechallenge with anti-EGFR"
2016-01-01 Sartore-Bianchi, A; Siena, S; Tonini, G; Bardelli, A; Santini, D.
PD-1 blockade therapy in renal cell carcinoma: current studies and future promises.
2015-01-01 Massari, F; Santoni, M; Ciccarese, C; Santini, D; Alfieri, S; Martignoni, G; Brunelli, M; Piva, F; Berardi, R; Montironi, R; Porta, C; Cascinu, S; Tortora, G.
Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?
2010-01-01 Rizzo, S; Bronte, G; Fanale, D; Corsini, L; Silvestris, N; Santini, D; Gulotta, G; Bazan, V; Gebbia, N; Fulfaro, F; Russo, A
The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide
2017-01-01 Del Re, M; Fogli, S; Derosa, L; Massari, F; De Souza, P; Crucitta, S; Bracarda, S; Santini, D; Danesi, R
Update on capecitabine alone and in combination regimens in colorectal cancer patients
2010-01-01 Silvestris, N; Maiello, E; De Vita, F; Cinieri, S; Santini, D; Russo, A; Tommasi, S; Azzariti, A; Numico, G; Pisconti, S; Petriella, D; Lorusso, V; Millaku, A; Colucci, G
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| 35 DNA DOUBLE STRANDS BREAK REPAIR GENES EXPRESSION ANALYSIS REVEAL RAD51 AS A NEW POTENTIAL BIOMARKER IN BREAST CANCER. | 1-gen-2010 | Barbano, R; Copetti, M; Perrone, G; Muscarella, La; Balsamo, T; Poeta, Ml; Valori, Vm; Latiano, T; Maiello, E; Carella, M; Pellegrini, F; Murgo, R; A Onetti Muda, ; Fazio, V. M.; Parrella, P | |
| 45 GENE EXPRESSION OF SOMATOSTATIN RECEPTOR SUBTYPES SSTR2a, SSTR3 AND SSTR5 IN PERIPHERAL BLOOD OF NEUROENDOCRINE LUNG CANCER AFFECTED PATIENTS | 1-gen-2010 | La, Muscarella; V, D'Alessandro; A La, Torre; M, Freda; M, Copetti; P, Parrella; R, Boragine; F, Pellegrini; E, Maiello; V, Frusciante; Fazio, V. M.; G, Vendemmiale | |
| 66 ABERRANT GENES PROMOTER METHYLATION IN NEURAL-CREST DERIVED TUMOURS | 1-gen-2010 | La, Muscarella; A La, Torre; P, Parrella; T, Balsamo; M, Bisceglia; R, Barbano; E, Perrella; Ml, Poeta; G, Melchionda; G, Merla; R, Pellicano; Fazio, V. M. | |
| Adjuvant colon cancer chemotherapy: where we are and where we'll go | 1-gen-2010 | Lombardi, L; Morelli, F; Cinieri, S; Santini, D; Silvestris, N; Fazio, N; Orlando, L; Tonini, G; Colucci, G; Maiello, E | |
| Best practices for the management of thymic epithelial tumors: A position paper by the Italian collaborative group for ThYmic MalignanciEs (TYME). | 1-gen-2018 | Imbimbo, M1; Ottaviano, M2; Vitali, M3; Fabbri, A4; Leuzzi, G5; Fiore, M6; Franceschini, D7; Pasello, G8; Perrino, M9; Schiavon, M10; Pruneri, G4; Dei Tos, Ap11; Sangalli, C12; Garassino, Mc3; Berardi, R13; Alessi, A14; Calareso, G15; Petrini, I16; Scorsetti, M17; Scotti, V18; Rosso, L19; Rea, F10; Pastorino, U5; Casali, Pg20; Ramella, S; Ricardi, U21; Abate-Daga, L22; Torri, V23; Trama, A24; Palmieri, G2; Marino, M25; Zucali, Pa9; TYME network, Collaborators. | |
| Bevacizumab-induced hypertension as a predictor of clinical outcome in metastatic colorectal cancer: An individual patient data-based pooled analysis of two randomized studies and a systematic review of the literature | 1-gen-2022 | Lombardi, P.; Rossini, D.; Crespi, V.; Germani, M. M.; Bergamo, F.; Pietrantonio, F.; Santini, D.; Allegrini, G.; Daniel, F.; Pagani, F.; Antoniotti, C.; Zaniboni, A.; Conca, V.; Latiano, T. P.; Boccaccino, A.; Passardi, A.; Tamburini, E.; Masi, G.; Di Maio, M.; Cremolini, C. | |
| Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma | 1-gen-2010 | Bronte, G; Rizzo, S; La Paglia, L; Adamo, V; Siragusa, S; Ficorella, C; Santini, D; Bazan, V; Colucci, G; Gebbia, N; Russo, A | |
| New molecular targets in bone metastases | 1-gen-2010 | Santini, D; Galluzzo, S; Zoccoli, A; Pantano, F; Fratto, Me; Vincenzi, B; Lombardi, L; Gucciardino, C; Silvestris, N; Riva, E; Rizzo, S; Russo, A; Maiello, E; Colucci, G; Tonini, G | |
| Overcoming dynamic molecular heterogeneity in metastatic colorectal cancer: Multikinase inhibition with regorafenib and the case of rechallenge with anti-EGFR" | 1-gen-2016 | Sartore-Bianchi, A; Siena, S; Tonini, G; Bardelli, A; Santini, D. | |
| PD-1 blockade therapy in renal cell carcinoma: current studies and future promises. | 1-gen-2015 | Massari, F; Santoni, M; Ciccarese, C; Santini, D; Alfieri, S; Martignoni, G; Brunelli, M; Piva, F; Berardi, R; Montironi, R; Porta, C; Cascinu, S; Tortora, G. | |
| Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy? | 1-gen-2010 | Rizzo, S; Bronte, G; Fanale, D; Corsini, L; Silvestris, N; Santini, D; Gulotta, G; Bazan, V; Gebbia, N; Fulfaro, F; Russo, A | |
| The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate/prednisone and enzalutamide | 1-gen-2017 | Del Re, M; Fogli, S; Derosa, L; Massari, F; De Souza, P; Crucitta, S; Bracarda, S; Santini, D; Danesi, R | |
| Update on capecitabine alone and in combination regimens in colorectal cancer patients | 1-gen-2010 | Silvestris, N; Maiello, E; De Vita, F; Cinieri, S; Santini, D; Russo, A; Tommasi, S; Azzariti, A; Numico, G; Pisconti, S; Petriella, D; Lorusso, V; Millaku, A; Colucci, G |
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile